Posted On: 02/24/2015 9:48:00 AM
Post# of 30066
Agreed, Chris. Amarantus didn't conduct the due diligence on ESS, and structure a deal to end the litigation and acquire the asset, just to turn around and sell it for a measly $15M. Nothing in their business model suggests they would make such a lame duck move.
The world market for ESS is expected to exceed $1 Billion per year. Phase 2 clinical trials are expected to initiate in Q2 of 2015, with a potential partnership planned for 2017. All of this info is available from the Amarantus web site.
Sale for $15 Million? Someone is smoking the wacky weed, or perhaps intelligent analysis is once again running amuck.
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
The world market for ESS is expected to exceed $1 Billion per year. Phase 2 clinical trials are expected to initiate in Q2 of 2015, with a potential partnership planned for 2017. All of this info is available from the Amarantus web site.
Sale for $15 Million? Someone is smoking the wacky weed, or perhaps intelligent analysis is once again running amuck.
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
(0)
(0)
